戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 mice reversed these exacerbated responses to allografting.
2 y disease (GCAD) and improves murine cardiac allografting.
3 derwent removal of the spleen before corneal allografting.
4 a significant advancement for clinical nerve allografting.
5 a significant advancement for clinical nerve allografting.
6 pand the clinical application of limb tissue allografting.
7  role in the elimination of malignancy after allografting.
8 dramatically reduced the acute toxicities of allografting.
9 he role of nonmyeloablative conditioning for allografting.
10 terolemic recipients at 15 and 30 days after allografting.
11 estigated in the setting of nonmyeloablative allografting.
12  lymphocytes to LNs in homeostasis and after allografting.
13 esting before as well as 20 to 40 days after allografting.
14 matched-related or -unrelated T-cell-replete allografting.
15 uld one treat the patient who relapses after allografting?
16 ndings on low-dose IL-2 treatment in corneal allografting and review recent studies focusing on the u
17 l types reached donor tissue at 1 week after allografting and similarly after syngeneic grafting.
18  being developed to decrease the toxicity of allografting and to enhance allogeneic anti-multiple mye
19  marrow stimulation, osteochondral auto- and allografting, and autologous chondrocyte implantation.
20 questions of initial therapy choice, role of allografting, and changes in therapy remains a fluid dis
21 the frog Xenopus by antibody depletion, skin allografting, and tumor transplantation.
22                                   This novel allografting approach, based on the use of postgrafting
23 dditional single-cell RNA-seq, ChIP-seq, and allografting assays.
24 ions were removed in mice undergoing corneal allografting (C57BL/10, H2(b) to BALB/c, H2(d)).
25                                              Allografting can be performed using progenitor cells fro
26 ng administered intravenously at the time of allografting (day 0) and on the following day (day 1).
27  anti-HLA class I and II antibodies prior to allografting, developed higher antibody titers.
28          During the first 3 days after liver allografting, donor B cells rapidly migrated from graft-
29            In 1994, a policy of double renal allografting (DUAL) was used at two centers within our l
30                                       Mixing-allografting experiments and proliferation indices showe
31 l after nontransplantation therapy and after allografting for CML in chronic phase.
32                  These results indicate that allografting for patients with MM can result in long-ter
33 row transplantation and subsequent epidermal allografting from the bone marrow transplant donor.
34  exploit the potent antileukemic efficacy of allografting from UCB, RD, or URD sources.
35                              The efficacy of allografting in acute lymphoblastic leukemia (ALL) is he
36     This study concludes that fetal striatal allografting in HD is safe.
37  cure are the excessive toxicity noted after allografting in multiple myeloma, contaminating tumor ce
38                                       Aortic allografting in syngeneic (group I; C3H-->C3H) and allog
39                                              Allografting is the treatment of choice for younger pati
40                      Comparison of syngeneic allografting methods enables reliable preservation and s
41 patibility complex (MHC)-matched murine skin allografting models that were highly contextual in their
42 icant and comparable to what is found in rat allografting models.
43 lated (MUD) donor T-cell-replete bone marrow allografting, obviating the need for additional prophyla
44                                    Epidermal allografting of these patients has decreased wound surfa
45    With a median follow-up of 552 days after allografting, overall survival is 78%.
46 d with 1 ml ALS on days -7 and 0 relative to allografting resulted in 100% permanent islet graft surv
47 th ALL in CR, reduced intensity conditioning allografting results in modest TRM, limited risk of rela
48 s by direct DNA injection, followed by liver allografting, results in donor-specific unresponsiveness
49 heir demonstrated enhancement of bone marrow allografting, suggests that the use of Tcm therapy in co
50 ngle-cell approaches, epigenetic assays, and allografting techniques to define a DFP state and the me
51 ular remission in patients who relapse after allografting; the mechanism for this graft-versus-leukem
52 eceived uniform conditioning, T-cell-replete allografting, then PTCy, mycophenolate mofetil, and tacr
53  regimens, designed to allow the benefits of allografting to be extended to patients in whom this pro
54 y allowing full extension of the benefits of allografting to the group of patients in highest need.
55 ated after nonmyeloablative conditioning and allografting using human leukocyte antigen (HLA)-mismatc
56         Five-year nonrelapse mortality after allografting was 18%, 95% related to GVHD or infections.
57 loped EBV-positive PTLD 8 to 94 months after allografting were uniformly treated with acyclovir and I
58 rrow transplantation (BMT) would allow organ allografting without chronic immunosuppressive therapy.